Now this is really interesting. UPenn spending a bit of its endowment and research funds to push this forward. Penn is a rich institution with an $8 billion endowment, and many endowments are big into venture capital investments. Nothing new there. Penn's intellectual domination of immuno-oncology is undeniable. Sooooo...
I think Penn sees this as a chance at a multibillion payoff for Penn, the kind of score that would move Penn from the second tier of the Ivy league into contention with Harvard-Yale-Princeton. That is a huge endorsement of what we have here. The people in the best position to know are funding the trial in an unusual move for academia...they must have convinced the University the potential here could be game changing for Penn.
plenty of business to be had with those who have cancer. fukushima radiation covering the USA will create generations of future patients.
Penn has an $8 billion endowment and will reap big royalties off any success. They will also get the fame as the School that invented the cancer vaccination. Big success here would be a life-changing event for Penn that pushes it into the Harvard, Yale, Princeton tier of the Ivy league. Why would they not want to fund it?
anything that gets us a second look is good. we are stupud undervalued right now.
yes I think we are better served by getting a cash rich partner than trying to do it all ourselves. such a deal would jump up our market value and enable future fundings to be with much less dilution
I hope this means INO will get trials going faster and results out faster. That has been a weak point.
SImple, it's because they have the experience needed to shepherd drugs through the trials
slowness seems to be a INO problem this year. ADXS annoucing a number of HPV combo trials, the latest with Medimmune